晚期黑素瘤的抗PD-1抗体疗法治疗现状与进展  

Anti-PD-1 therapy for advanced melanoma

作　　者：王欣[1,2] 张献全[2] 

机构地区：[1]重庆医科大学研究生院,400010 [2]重庆医科大学附属第二医院肿瘤科

出　　处：《实用医药杂志》2015年第11期992-994,共3页Practical Journal of Medicine & Pharmacy

摘　　要：近年来恶性黑素瘤发病率有明显上升趋势,其对单纯放疗及化疗均不敏感;该肿瘤属免疫原性较高的肿瘤[1]。免疫抑制性分子程序性细胞死亡受体1(PD-1)的研究在免疫靶向治疗中具有里程碑式的意义,并且FDA已加速批准两种抗PD-1药物的使用。2015年,美国临床肿瘤学会(ASCO)上有大量关于黑素瘤及抗PD-1药物的诊治进展的重要报道。在本文中,笔者讨论了抗PD-1药物现状及与其他免疫抑制药及靶向联合治疗黑素瘤的进展,为下一步研究提供方向。In recent years,the incidence of malignant melanoma is obviously increasing,which is not sensitive to radiotherapy and chemotherapy;it is a kind of tumor with higher immunogenicity. Immunosuppressive molecular programmed cell death receptor 1 （PD-1） has a landmark significance in the immune targeting therapy, and FDA has accelerated the approval of two anti-PD-1 drugs used in the United States. In 2015,American Society of Clinical Oncology （ASCO） reports a large number of important experiments about using anti PD-1 drugs in melanoma and other tumors. In this review,authors discuss the status quo of anti-PD-1 drugs,and the progress of the treatment combining anti-PD-1 with other immunotherapeutic agents or targeted therapy,so as to the provide direction for future research.

关 键 词：黑素瘤 程序性细胞死亡受体1(PD-1) 免疫疗法 皮肤肿瘤 

分 类 号：R739.5[医药卫生—肿瘤]